drugset

drugset / Trial / NCT00822354

Tadalafil for the Treatment of Raynaud's

NCT00822354 ↗

Completed 10 enrolled Northwestern University Eli Lilly and Company · collab

RandomizedCrossoverDouble-blindTreatment

Summary

The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.

Timeline

Start: 2008-09
Primary completion: 2010-02
Completion: 2010-04

Publications

Maltez N, Maxwell LJ, Rirash F, Tanjong Ghogomu E, Harding SE, Tingey PC, Wells GA, Tugwell P, Pope J. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD014089. doi: 10.1002/14651858.CD014089.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tadalafil	Small molecule	20 mg	Oral

Indications